Which medications in the drug class Monoclonal Antibodies, Endocrine are used in the treatment of Osteoporosis?

Updated: Sep 26, 2019
  • Author: Monique Bethel, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

Monoclonal Antibodies, Endocrine

Monoclonal antibodies such as denosumab (Prolia) inhibit osteoclast formation, decrease bone resorption, increase BMD, and reduce the risk of fracture. Another monoclonal antibody, romosozumab, binds sclerostin, a regulatory factor in bone metabolism.

Denosumab (Prolia)

Denosumab binds to the receptor activator of nuclear factor-kappa B ligand (RANKL), a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, which are the cells that are responsible for bone resorption. It is indicated to increase bone mass in men and postmenopausal women with osteoporosis at high risk for fracture. It is also indicated for men at high risk for fracture who are receiving androgen deprivation therapy for nonmetastatic prostate cancer. Additionally, it is indicated for glucocorticoid-induced osteoporosis in men and women at high risk of fracture. The general dosage is 60 mg every 6 months as an SC injection in the upper arm, upper thigh, or abdomen. Patients should be instructed to take 1000 mg of calcium daily and at least 400 IU of vitamin D daily.

Romosozumab (Evenity)

Monoclonal antibody (IgG2) that binds sclerostin, a regulatory factor in bone metabolism. Sclerostin inhibition increases bone formation and, to a lesser extent, decreases bone resorption. It is indicated for osteoporosis treatment in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture. It is also indicated for patients who have failed or are intolerant to other available osteoporosis therapy.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!